Skip to content

HIAS II - Study of Nutritional Supplementation in Hospitalized Children With Persistent Diarrhea or Malnutrition

Prospective Double Blind Randomized Clinical Trial of Alanyl-Glutamine or Glycine in Hospitalized Children With Persistent Diarrhea or Malnutrition.

Status
Withdrawn
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00133562
Enrollment
108
Registered
2005-08-23
Start date
2004-08-31
Completion date
2006-05-31
Last updated
2008-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diarrhea, Malnutrition, Other Nutritional Deficiencies

Keywords

Malnutrition, pediatric, Brazil, alanyl-glutamine

Brief summary

This study will determine the effect of 7 days supplementation of alanyl-glutatime or glycine on the damaged intestinal barrier function on day 8 in children with persistent diarrhea or malnutrition.

Detailed description

The purpose of this study is to determine the effect of 7 days supplementation of alanyl-glutamine or glycine on the damaged intestinal barrier function, measured by lactulose/mannitol test on day 8, in children with persistent diarrhea or malnutrition; on diarrhea frequency and duration, weight gain, protein loss, intestinal inflammation, and lactoferrin excretion.

Interventions

DRUGGlycine

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)
CollaboratorNIH
University of Virginia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
3 Months to 3 Years
Healthy volunteers
No

Inclusion criteria

1. Children ages 3 to 36 months with a history of persistent diarrhea (3 or more unformed stools/day) for \>2 weeks or height-for-age Z-score (HAZ) less than negative 1, which is the median of HAZ score in children at HIAS. 2. Be an inpatient and willing to stay for 7 nights at HIAS. 3. Child´s parent or guardian must sign informed consent..

Exclusion criteria

1. Children exclusively breast-fed (Reason: The diet needs to be controlled in order to evaluate the study treatment effect) 2. Children who participated in the community study or any other study within the past two years (Reason: The children in the community study will have received glutamine.) 3. Children with suspected other illnesses as indicated by fever \>102º F at time of screening off antipyretics 4. Children with suspected systemic disease at the time of screening including but not limited to shock, meningitis, sepsis, pneumonia, tuberculosis, varicella 5. Severe malnutrition defined as HAZ \<-3 or WAZ \<-3.5 or any child weighing \<10 lbs. (4.5 kg) or any child with a weight-to-height ratio \<60% of the NCHS age adjusted norm.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026